Arena Sees Phase III Path For Etrasimod After Atopic Dermatitis Miss

Analysts Agreed The S1P Receptor Modulator Should Advance

 
• By Mandy Jackson

Arena said its S1P receptor modulator missed the primary endpoint in a Phase IIb trial but data from patients with uninterrupted treatment justify moving etrasimod into a pivotal program.

Pathway in the garden outdoor, forward stepping stones or pebbled in the grass lawn.
Arena identified a path forward for etrasimod in atopic dermatitis • Source: Shutterstock

More from Clinical Trials

More from R&D